CCR8 and neoplasm: Several monoclonal antibodies targeting CCR8 are currently under preclinical or early clinical investigation, aiming to selectively deplete CCR8+ tumor-infiltrating T cells or enhance anti-tumor immune responses; antibodies with Fc-effector functions have shown the capacity to eliminate intratumoral Tregs while sparing peripheral immune tolerance electively (50, 50, 52).